PHARMACY

Upsher-Smith recognized with HDA DIANA award

BY David Salazar
Left to right: HDA president and CEO John Gray, Upsher-Smith senior director national accounts Brad Leonard, Upsher-Smith national accounts manager Mike Muzetras and HDA chairman and Dakota Drug CEO Ted Scherr. 
 
MAPLE GROVE, Minn. — The Healthcare Distribution Alliance (formerly the Healthcare Distribution Management Association) has honored Upsher-Smith Laboratories with a Distribution Industry Award for Notable Achievement in Healthcare Award. The DIANA award was given to Upsher-Smith for “Best Overall Branded Pharmaceutical Product Manufacturer with Less than $300 Million in Sales.”
 
Upsher-Smith has received the award four times in the past six years, and it was one of 12 DIANA award winners honored at the HAD’s 2016 Business and Leadership Conference held in Colorado Springs, Colo. on June 13. 
 
“We are honored to have been selected for a DIANA award, and especially to be recognized again as the year's 'Best Overall Branded Pharmaceutical Product Manufacturer' in our sales category,” Upsher-Smith VP global sales Scott Hussey, who was at the awards ceremony, said. “Upsher-Smith strives to meet and exceed current standards of pharmaceutical manufacturing excellence, and we are proud to be acknowledged for our efforts to bring high-quality, high-value products to patients across the nation.”
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves Gilead’s hepatitis C drug Epclusa

BY David Salazar
SILVER SPRING, Md. — The Food and Drug Administration has approved Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg), the company announced earlier this week. Epclusa is a single tablet treatment for adults with genotype 1-6 chronic hepatitis and for patients with hepatitis C genotype 2 and 4 without the need for ribavirin. The drug for 12 weeks was approved for use in patients without cirrhosis or with compensated cirrhosis and in combination with ribavirin. 
 
“Today’s approval represents a significant advance for patients with HCV genotypes 2 and 3, who previously required more complex and costly regimens,” said John Milligan, Ph.D., President and Chief Executive Officer of Gilead. “As the first and only pan-genotypic cure for hepatitis C, Epclusa has the potential to eliminate the need for genotype testing, which can be a barrier to treatment in certain resource-constrained settings. We look forward to making Epclusa available to patients around the world as quickly as possible.”
 
Epclusa received Priority Review and Breakthrough Therapy designations from the FDA. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

RediClinic boosts health alliances

BY Richard Monks

In recent months, RediClinic — which operates 43 clinics in Rite Aid stores in the Philadelphia, Baltimore/Washington, D.C., and Seattle markets, as well as 35 clinics in H-E-B grocery stores in Houston, Austin and San Antonio — has continued to form alliances with local healthcare providers. The company continues to strengthen its ability to offer convenient health care to more patients through its partnerships with local healthcare providers.

(To view the full Category Review, click here.)

One of the most recent of these alliances came in February when RediClinic and Aria Health, a large healthcare provider in eastern Pennsylvania, teamed up on a deal that the companies say will offer greater convenience, increased access and more affordable healthcare to residents in these markets.

Earlier, RediClinic struck a similar deal with the Seattle-area not-for-profit healthcare organization MultiCare Health System that has seen the companies jointly operate 11 RediClinics inside Rite Aid pharmacies in the Puget Sound region.

RediClinic CEO Web Golinkin has said that partnerships like these coupled with Rite Aid’s heritage as a healthcare provider signals a bright future for RediClinic. The company already has provided nearly 2 million patients with easy access to high-quality, affordable health care, and that number should only continue to rise in the coming years.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?